natgillin/translations-raw huggingface dataset:
Common side effects (may affect up to 1 in 10 people) - Pain (even if medicines are used to prevent or lessen pain caused by the removal of burnt tissue) - Infection of the burn wound - Complications of the wound including; wound opening, wounds drying out and breaking down and failure of skin grafts to heal properly
Pogosti neželeni učinki (prizadenejo lahko največ 1 od 10 bolnikov) - bolečina (tudi ob uporabi zdravil za preprečevanje ali blaženje bolečine, ki jo povzroči odstranjevanje opečenega tkiva) - okužba opeklinske rane - zapleti z rano, vključno z odprtjem rane, izsušitvijo rane in raztrganjem ali neustreznim celjenjem kožnih presadkov
There is limited pharmacokinetic data in patients with TBSA of more than 15%.
Pri bolnikih z opeklinami na več kot 15 % CPT so farmakokinetični podatki omejeni.
• The gel should be prepared at the patient's bedside.
• Gel morate pripraviti ob bolnikovi postelji.
To prevent wound-healing problems, the treated burn wound will be covered as soon as possible by temporary or permanent skin substitutes or dressings.
Da preprečite težave s celjenjem rane, bo obdelana opeklinska rana takoj, ko je mogoče, prekrita z začasnim ali stalnim kožnim nadomestkom ali oblogo.
The AUC from time zero to 48 hours after administration (AUClast) was 43,400 ± 46,100 ngh/ml (mean ± SD) for the group of 15 patients, with a range of 4560-167,000 ngh/ml.
AUC od časa nič do 48 ur po uporabi (AUClast) je bil 43.400 ± 46.100 ngh/ml (povprečje ± SD) za skupino 16 bolnikov, z razponom 4.560-167.000 ngh/ml.
Each NexoBrid vial, gel, or reconstituted gel should be used for a single patient only.
Vsako vialo zdravila NexoBrid gel ali rekonstituiranega gela uporabite samo za enega bolnika.
• When opening the gel bottle, it must be confirmed that the tamper-evident ring is separating from the bottle's cap.
• Pri odpiranju stekleničke z gelom morate preveriti, da se je varnostni obroček ločil od zaporke steklenice.
Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.
Z drgnjenjem ne boste odstranili neodluščenih eshar na predelih, kjer so ostale.
• The NexoBrid powder and gel are sterile.
• Zdravilo NexoBrid prašek in gel sta sterilna.
If the tamper-evident ring was already separated from the cap before opening, the gel bottle must be discarded and another, new gel bottle used.
Če je bil varnostni obroček že odtrgan od zaporke, preden ste jo odprli, morate steklenico z gelom zavreči in uporabite drugo, novo steklenico z gelom.
Cross-sensitivity
Križna senzibilizacija
Benefit/risk assessment should include consideration of the greater frequency of concomitant disease or other medicinal product therapy in the elderly.
Pri oceni razmerja med koristmi in tveganjem je treba upoštevati, da je pri starejših bolnikih pogostnost sočasnih obolenj ali sočasnega zdravljenja z drugimi zdravili večja.
NexoBrid may reduce the ability of your blood to form clots, which increases the risk of bleeding.
Zdravilo NexoBrid lahko zmanjša sposobnost strjevanja krvi in s tem poveča tveganje za krvavitev.
NexoBrid should be used with caution if you have a general tendency to bleed, a stomach ulcer, blood poisoning, or another condition that could cause you to bleed.
Zdravilo NexoBrid je treba uporabljati previdno, če ste na splošno nagnjeni h krvavitvam, razjedi želodca, zastrupitvi krvi ali drugim stanjem, ki lahko povzročijo krvavitev.
It is unknown whether concentrate of proteolytic enzymes enriched in bromelain or its metabolites are excreted in human milk.
Ni znano, ali se koncentrat proteolitičnih encimov, obogaten z bromelainom, ali njegovi presnovki izločajo v materino mleko.
NexoBrid may: - increase the effects of certain medicines that are inactivated by a liver enzyme called CYP2C8 and CYP2C9.
Zdravilo NexoBrid lahko: - poveča učinke nekaterih zdravil, ki jih jetrna encima, imenovana CYP2C8 in CYP2C9, deaktivirata.
Since the safe use of NexoBrid during pregnancy has not yet been established, NexoBrid is not recommended during pregnancy.
Ker varnosti uporabe zdravila NexoBrid med nosečnostjo še niso dokazali, zdravila NexoBrid ne uporabljajte pri nosečnicah.
No interaction studies with NexoBrid have been performed.
Študij medsebojnega delovanja z zdravilom NexoBrid niso izvedli.
In NexoBrid studies wounds with visible dermal remnants were allowed to heal by spontaneous epithelialisation.
V študijah z zdravilom NexoBrid so pustili, da so se rane z vidnimi ostanki kože zacelile s spontano epitelializacijo.
The gel is clear and colourless.
Gel je prozoren in brezbarven.
• The debrided area must be covered immediately by temporary or permanent skin substitutes or dressings to prevent desiccation and/or formation of pseudoeschar and/or infection.
• Očiščen predel morate takoj prekriti z začasnim kožnim nadomestkom ali stalnim kožnim presadkom ali oblogo, da se ne osuši in/ali ne nastanejo psevdoeshare in/ali okužbe.
In studies without antibacterial soaking, pyrexia or hyperthermia was reported in 35.6% of NexoBridtreated patients compared with 18.6% in control patients.
V študijah brez antibakterijskega namakanja so o pireksiji ali hipertermiji poročali pri 35,6 % bolnikov, zdravljenih z zdravilom NexoBrid, v primerjavi z 18,6 % bolnikov iz kontrolne skupine.
The efficacy of NexoBrid in humans was evaluated, compared to standard of care, in a randomised, multi-centre, multi-national, open-label, confirmatory phase 3 study in hospitalised patients with deep partial- and/or full-thickness thermal burns of 5 to 30% Total Body Surface Area (TBSA), but with total burn wounds of no more than 30% TBSA.
Učinkovitost zdravila NexoBrid pri ljudeh je bila ocenjena glede na standardno nego v randomizirani, multicentričini, multinacionalni, odprti, potrditveni študiji 3. faze pri hospitaliziranih bolnikih z globokimi dermalnimi in subdermalnimi opeklinami 5 do 30 % celotne površine telesa (CPT) in s skupnimi opeklinskimi ranami do 30 % CPT.
Non-autografted wounds (ITT)
Rane brez avtotransplantata (ITT)
In phase 2 and phase 3 clinical studies, certain types of wound complications were reported more frequently in the NexoBrid group than in the group treated according to the study sites' Standard of Care (SOC).
V kliničnih študijah 2. in 3. faze so o nekaterih vrstah zapletov z rano poročali pogosteje v skupini z zdravilom NexoBrid, kot pri skupini, zdravljeni v skladu s standardno terapijo.
• The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser).
• Površino, s katere želite odstraniti esharje, morate obdati z adhezivno pregrado iz sterilnega parafinskega mazila, ki ga nanesete nekaj centimetrov zunaj zdravljenega predela (uporabite razdeljevalec).
There is only limited safety data from the use in the paediatric population.
Podatkov o varnosti pri pediatrični populaciji je malo.
Direct contact with the eyes should be avoided.
Preprečite neposredni stik z očmi.
Before use, the powder must be mixed with the gel producing a uniform gel.
Pred uporabo je treba prašek zmešati z gelom, da nastane enakomeren gel.
It is not known if NexoBrid application has any clinically relevant effect on haemostasis.
Ni znano, ali ima nanos zdravila NexoBrid klinično pomemben učinek na hemostazo.
NexoBrid should only be applied by trained healthcare professionals in specialist burn centres.
Zdravljenje z zdravilom NexoBrid lahko izvaja le usposobljeni zdravstveni delavec v specializiranem centru za opekline.
• Summary of Product Characteristics and Patient Information Leaflet
• Povzetek glavnih značilnosti zdravila in navodilo za uporabo
If too much NexoBrid is used If too much NexoBrid gel is applied on a burn wound, excess gel may be wiped off.
Če je bil uporabljen preveliki odmerek zdravila NexoBrid Če se na rano nanese preveč zdravila NexoBrid gel, se presežek gela obriše.
NexoBrid contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is produced from an extract from the stem of the pineapple plant.
Zdravilo NexoBrid vsebuje mešanico encimov, imenovano "koncentrat proteolitičnih encimov, obogatenih z bromelainom", ki se izdelujejo iz ekstrakta iz stebla rastline ananasa.
The use of NexoBrid during pregnancy is not recommended.
Uporaba zdravila NexoBrid med nosečnostjo ni priporočljiva.
The efficacy of eschar removal was evaluated by determining the percentage of wound area left with eschar that required further removal by excision or dermabrasion, and the percentage of wounds requiring such surgical removal.
Učinkovitost odstranitve eshar so ocenili z ugotavljanjem odstotka predela rane, na katerem so eshare ostale, in kjer jih je bilo treba naknadno odstraniti z ekscizijo ali dermabrazijo, in odstotkom ran, pri katerih je bila potrebna kirurška odstranitev.
The available data are limited and NexoBrid should not be used in patients younger than 18 years.
Razpoložljivih podatkov je malo, zato se zdravila NexoBrid ne sme uporabljati pri bolnikih, mlajših kot 18 let.
See also section 4.4.
Glejte poglavje 4.4.
• The method of preparation of NexoBrid and of its application to wound area
• Način priprave zdravila NexoBrid in aplikacije na predel rane
NexoBrid should be used within 15 minutes after mixing the powder with the gel.
Zdravilo NexoBrid uporabite v 15 minutah po mešanju praška z gelom.
The treated area must be rubbed until the appearance of a pinkish surface with bleeding points or a whitish tissue.
Zdravljeni predel morate drgniti, dokler ne opazite rožnato površino s krvavimi pikicami ali belkasto tkivo.
• The wound must be cleaned thoroughly and the superficial keratin layer or blisters removed from the wound area, as the keratin will isolate the eschar from direct contact with NexoBrid and prevent eschar removal by NexoBrid.
• Rano morate temeljito očistiti in odstraniti odvečne plasti keratina ali mehurje s predela rane, saj bo keratin preprečil neposreden stik eshar z zdravilom NexoBrid in preprečil, da bi zdravilo NexoBrid eshare odstranilo.
Treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:5 (0.16g per g of mixed gel) in patients with deep partial- and/or full-thickness burns within the framework of a clinical study did not result in significantly different safety findings when compared to treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:10 (0.09 g per 1g of mixed gel).
Zdravljenje s koncentratom proteolitičnih encimov, obogatenih z bromelainom, pripravljenim v razmerju prašek:gel 1:5 (0,16 g na g mešanega gela) pri bolnikih z globokimi dermalnimi in subdermalnimi opeklinami v okviru klinične študije ni imelo za posledico značilno drugačnih izsledkov o varnosti, ko so jih primerjali z zdravljenjem s koncentratom proteolitičnih encimov, obogatenih z bromelainom, pripravljenimi v razmerju prašek:gel 1:10 (0,09 g na 1 g mešanega gela).
A single intravenous infusion of a solution prepared from NexoBrid powder in the mini-pig was well tolerated at dose levels of up to 12 mg/kg (achieving plasma levels 2.5fold of the human plasma level after application of the clinical proposed dosage to 15% TBSA) but higher doses were overtly toxic, causing haemorrhage in several tissues.
Enojno intravensko infuzijo raztopine, pripravljene iz zdravila NexoBrid prašek, so mini-prašički dobro prenašali pri ravneh odmerkov do 12 mg/kg (dosežene ravni v plazmi so bile 2,5-kratne od ravni v plazmi pri ljudeh po nanosu klinično predlaganega odmerka na 15 % CPT), medtem ko so bili višji odmerki zelo toksični in so v številnih tkivih povzročili krvavitve.
What NexoBrid looks like and contents of the pack
Izgled zdravila NexoBrid in vsebina pakiranja
No dose adjustment is required.
Odmerka ni treba prilagajati.
The NexoBrid gel must fill the entire occlusive dressing, and special care should be taken not to leave air under this occlusive dressing.
Zdravilo NexoBrid gel mora zapolniti celotno okluzivno oblogo, pri čemer je potrebna posebna pozornost, da pod okluzivno oblogo ne pride zrak.
• The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
• Adhezivno pregrado morate odstraniti s sterilnim topim inštrumentom (npr. paličico za jezik).
Using NexoBrid may reduce the need for, or the extent of, surgical removal of burnt tissue and/or skin transplantation.
Z uporabo zdravila zdravila NexoBrid se lahko zmanjšata potreba in obseg kirurške odstranitve opeklega tkiva in/ali presaditve.
The frequencies of the adverse reactions presented below reflect the use of NexoBrid to remove eschar from deep partial- or full-thickness burns in a regimen with local antibacterial prophylaxis, recommended analgesia, as well as coverage of the wound area after application of NexoBrid for 4 hours with an occlusive dressing for containment of NexoBrid on the wound.
Spodaj predstavljene pogostnosti neželenih učinkov izhajajo iz uporabe zdravila NexoBrid za odstranjevanje eshar z globokih dermalnih in subdermalnih opeklin pri režimu z lokalno antibakterijsko profilakso, priporočeno analgezijo ter prekrivanjem predela rane po nanosu zdravila NexoBrid za 4 ure z okluzivno oblogo, ki zadrži zdravilo NexoBrid na rani.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
Prevention of wound complications
Preprečevanje zapletov z rano
If you notice any of these signs or symptoms, inform your doctor or caregiver immediately.
Če opazite katere koli od teh znakov ali simptomov, takoj obvestite svojega zdravnika ali negovalca.
NexoBrid is used in adult patients to remove burnt tissue from deep or partially deep burn wounds of the skin.
Zdravilo NexoBrid se uporablja pri odraslih bolnikih za odstranjevanje opečenega tkiva iz subdermalnih ali dermalnih opeklinskih ran kože.
Blood pressure should be monitored in patients receiving ACE inhibitors
Pri bolnikih, ki prejemajo zaviralce ACE, je treba spremljati krvni tlak.
If you notice any of these symptoms or signs, inform your doctor or caregiver immediately.
Če opazite katere koli od teh simptomov ali znakov, takoj obvestite svojega zdravnika ali negovalca.
Warnings and precautions Talk to your doctor or nurse before NexoBrid is used if
Opozorila in previdnostni ukrepi Pred uporabo zdravila NexoBrid se pogovorite s svojim zdravnikom ali medicinsko sestro,
If NexoBrid goes into the eyes, wash them with lots of water for at least 15 minutes.
Če zdravilo NexoBrid pride v oči, jih vsaj 15 minut izpirajte z veliko vode.
The mixture of enzymes in NexoBrid dissolves burn wound eschar.
Mešanica encimov v zdravilu NexoBrid raztopi eshar z opeklinske rane.
NexoBrid is not indicated for use in patients younger than 18 years.
Zdravilo NexoBrid ni indicirano za uporabo pri bolnikih, mlajših od 18 let.
MediWound Germany GmbH 65428 Rüsselsheim Germany
MediWound Germany GmbH 65428 Rüsselsheim Nemčija
Concentrate of proteolytic enzymes enriched in bromelain is a debriding agent, applied topically for removal of eschar in deep partial- and full-thickness burns.
Koncentrat proteolitičnih encimov, obogatenih z bromelainom, je čistilna snov, ki se topikalno nanaša za odstranitev eshar pri globokih dermalnih in subdermalnih opeklinah.
• NexoBrid gel should be prepared at the patient's bedside.
• Gel zdravila NexoBrid morate priprabiti ob bolnikovi postelji.
Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement.
Razmisliti je treba tudi o namestitvi trajnih kožnih prekritij (npr. avtotransplantatov) na globoke dermalne rane kmalu po očiščenju z zdravilom NexoBrid.
As a precautionary measure, you should not breast-feed for at least 4 days after NexoBrid application.
Kot previdnostni ukrep vsaj 4 dni po nanosu zdravila NexoBrid ne smete dojiti.
• The dissolved eschar must be removed from the wound by wiping it away with a sterile bluntedged instrument.
• Odluščene eshare morate odstraniti z rane tako, da jih obrišete s sterilnim topim inštrumentom.
The age range in the SOC group was 5.1 to 55.7 years.
Razpon starosti v skupini, zdravljeni s standardno nego, je bil 5,1 do 55,7 let.
NexoBrid should be left in contact with the burn for a duration of 4 hours.
Zdravilo NexoBrid naj bo 4 ure v stiku z opeklino.
NexoBrid was applied once to the burn wound at a dose of 2 g NexoBrid Powder/20 g gel/100 cm of skin.
Zdravilo NexoBrid so na opeklinsko rano nanesli enkrat v odmerku 2 g zdravila NexoBrid prašek/20 g gela/100 cm kože.
When applying a permanent skin cover (e.g., autograft) or temporary skin substitute (e.g., allograft) to a freshly enzymatically debrided area, care should be taken to clean and refresh the debrided bed by, e.g., brushing or scraping to allow dressing adherence.
Pri nanosu stalnega kožnega presadka (npr. avtotransplantata) ali začasnega kožnega nadomestka (npr. alotransplantata) na svež encimsko očiščen predel, bodite pozorni na čiščenje in osvežitev očiščene rane, npr. s ščetkanjem ali strganjem, da se obloga sprime.
SN: {number}
< PC: {številka} SN: {številka} NN: {številka}>
The range of total dose applied was 5 to 30 g concentrate of proteolytic enzymes enriched in bromelain from NexoBrid.
Razpon skupnega nanesenega odmerka je bil 5 do 30 g koncentrata proteolitičnih encimov, obogatenih z bromelainom iz zdravila NexoBrid.
Before prescribing NexoBrid
Pred predpisovanjem zdravila NexoBrid
Eyes should be carefully protected during treatment of facial burns using adhesive barrier petroleum ointment.
Med zdravljenjem obraznih opeklin je treba oči skrbno zaščititi z adhezivno pregradno vazelinsko mastjo.
• The wound must be wiped thoroughly first with a large sterile dry gauze or napkin, followed by a sterile gauze or napkin that has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution.
• Rano morate temeljito obrisati z veliko sterilno suho gazo ali brisačo, nato pa s sterilno gazo ali brisačo, namočeno v sterilno izotonično 0,9-odstotno raztopino natrijevega klorida (9 mg/ml).
Wound infection
okužba rane
Powder 2 g
prašek 2 g
NexoBrid must be stored upright to keep the gel at the bottom of the bottle and in the original package to protect from light.
Zdravilo NexoBrid shranjujte pokončno, da ostane gel na dnu steklenice, in v originalni ovojnini za zagotovitev zaščite pred svetlobo.
• The need for wound cleansing and preparation before treatment with o Application of a dressing soaked with an antibacterial solution for two hours before NexoBrid application o Protection of surrounding skin areas
• Potreba po čiščenju rane in pripravi pred zdravljenjem z o nanosom obloge namočene v antibakterijsko raztopino za dve uri, pred nanosom zdravila Nexobrid o zaščito okoliških področij kože
• Within 15 minutes of mixing, NexoBrid must be applied topically to the burn wound, at a thickness of 1.5 to 3 millimetres.
• V roku 15 minut od mešanja morate zdravilo NexoBrid topikalno nanesti na opeklinsko rano z debelino plasti 1,5 do 3 milimetre.
NexoBrid powder Ammonium sulphate Acetic acid
NexoBrid prašek amonijev sulfat ocetna kislina
Direct contact of NexoBrid with the eyes should be avoided.
Preprečite neposredni stik zdravila NexoBrid z očmi.
Pack size of 1 vial of powder and 1 bottle of gel.
Velikost pakiranja 1 viala s praškom in 1 steklenička z gelom.
The paraffin layer must not come into contact with the area to be treated in order to avoid covering the eschar, thus isolating the eschar from direct contact with NexoBrid.
Parafinska plast ne sme priti v stik s predelom, ki ga želite zdraviti, da ne prekrije eshar in prepreči, da bi prišle v neposredni stik z zdravilom NexoBrid.
Preparation of patient and wound area
Priprava bolnika in predela rane
To prevent possible irritation of abraded skin by inadvertent contact with NexoBrid and possible bleeding from the wound bed, acute wound areas such as lacerations or escharotomy incisions should be protected by a layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze).
Da preprečite možno draženje odrgnjene kože zaradi nenamernega stika z zdravilom NexoBrid in morebitno krvavenje iz posteljice rane, je na rani akutna področja, kot so raztrganine ali esharotomne zareze, treba zaščititi s plastjo sterilnega mastnega mazila ali z mastno oblogo (npr. z gazo z vazelinom).
(mean ± SD) Time to complete wound closure (time from ICF**) Number of patients Days to closure of last wound (mean ± SD) Time to successful eschar removal Number of patients Days (mean ± SD) from injury Days (mean ± SD) from consent Patients not reported to have successful eschar removal Measured at first session, if there was more than one surgery session.
SD) Čas do popolnega zaprtja rane (čas od PRS**) Število bolnikov Dnevi do zaprtja zadnje rane (povprečje ± SD) Čas do uspešne odstranitve eshar Število bolnikov Dnevi (povprečje ± SD) od poškodbe Dnevi (povprečje ± SD) od prostovoljnega soglasja Bolniki, pri katerih niso poročali o uspešni odstranitvi eshar 1 Izmerjeno pri prvi obravnavi, če je bilo kirurških obravnav več.
In addition, a delayed-type allergic skin reaction (cheilitis) after longer-term dermal exposure (mouthwash) as well as suspected sensitisation following oral exposure and following repeated occupational airway exposure have been reported.
Poleg tega so poročali o zakasnelih alergijskih kožnih reakcijah (heilitis) po daljši dermalni izpostavljenosti (ustna voda) in o sumu na senzibilizacijo po peroralni izpostavitvi in po večkratni poklicni izpostavljenosti dihalnih poti.
Removal of NexoBrid
Odstranjevanje zdravila NexoBrid
In studies where analgesia was provided in NexoBrid-treated patients on an on-demand basis, local pain was reported in 23.3% of patients treated with NexoBrid and in 11.4% of the control patients.
V študijah, kjer so analgetike pri bolnikih, zdravljenih z zdravilom NexoBrid, uporabljali po potrebi, so o lokalni bolečini poročali pri 23,3 % bolnikov, zdravljenih z zdravilom NexoBrid in pri 11,4 % bolnikov iz kontrolne skupine.
The powder is off-white to light tan and the gel is clear and colourless.
Prašek je belkast do svetlorjav, gel je prozoren in brezbarven.
Breast-feeding should be discontinued at least 4 days from NexoBrid application initiation.
Od uvedbe zdravila NexoBrid je treba za vsaj 4 dni prenehati z dojenjem.
In case of skin exposure, NexoBrid must be rinsed off with water.
V primeru izpostavljenosti kože morate zdravilo NexoBrid izpirati z vodo.
There are no data from the use of NexoBrid in pregnant women.
Podatkov o uporabi zdravila NexoBrid pri nosečnicah ni.
NexoBrid should not be used in chemical burn wounds, contaminated wounds and wounds where NexoBrid could come in contact with foreign materials (for example, implants, pacemakers, and shunts) or large blood vessels, the eyes or other important body parts.
Zdravila NexoBrid ne uporabljajte pri kemičnih opeklinskih ranah, kontaminiranih ranah in ranah, pri katerih lahko zdravilo NexoBrid pride v stik s tujki (na primer vsadki, spodbujevalniki in šanti), velikimi žilami, očmi ali drugimi pomembnimi deli telesa.
Cross-sensitivity between bromelain and papain as well as latex proteins (known as latex-fruit syndrome), bee venom, and olive tree pollen has been reported in the literature.
V literaturi poročajo o križni senzibilizaciji med bromelainom in papainom ter beljakovinami lateksa (znan kot sindrom alergije na lateks in sadje), čebeljim strupom in pelodom oljke.
• Before application of the grafts or primary dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or scraping to allow dressing adherence.
• Pred nanosom presadka ali primarnega ovoja je treba očiščeno posteljico rane očistiti in osvežiti, npr. s ščetkanjem ali strganjem, da se obloga sprime.
Deep partial-thickness wounds autografted* Number of wounds % of wounds autografted % of wound area autografted (mean ± SD)
Globoke dermalne rane z avtotransplantatom* Število ran % ran z avtotransplantatom % predela ran z avtotransplantatom (povprečje ± SD)
Powder 5 g
prašek 5 g